ArticleAnnals of surgical oncology2026
Validation of Updated Sarculator Nomogram for Primary Retroperitoneal Sarcoma in the United States.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Optimising Clinical Outcomes Following R1 Resection in Soft Tissue Sarcoma: An Evidence-Based Approach.Current treatment options in oncology · 2026Review
- Association of surgical resection with survival in retroperitoneal leiomyosarcoma based on SEER propensity score matching and machine-learning models.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Sarculator nomogram for retroperitoneal sarcoma (RPS) was recently updated to include the variable 'hospital volume', validated using primarily non-U.S.-based patient data. We sought to validate the updated nomogram using U.S. data, examine various cutoffs for high-volume center (HVC) designation (≥ 13 cases per year), and investigate factors that may further improve the nomogram.
methodsA nationwide retrospective analysis using the National Cancer Database evaluated patients with RPS from 2010 to 2021. The Cox proportional hazards model was used to evaluate the impact of treatment at HVCs on overall survival (OS) using multiple case/year definitions. A model mimicking Sarculator's parameters was constructed then compared against sequential additions of variables found to be predictive in the initial analysis.
resultsA total of 4537 patients were included, 352 of whom were treated at HVCs. Treatment at an HVC using this cutoff was associated with improved OS (hazard ratio [HR] 0.62; 95% confidence interval [CI] 0.43-0.90), whereas there was no association with OS using cutoffs of 10, 7, or 5 cases per year. Female sex (HR 0.81; 95% CI 0.69-0.94) and Charlson Comorbidity Index (CCI) score (HR 1.23; 95% CI 1.02-1.49) predicted improved survival. The addition of the HVC variable to the baseline model improved the fit of the model (likelihood ratio 10.23; p < 0.01) with the C-index going from 0.7126 to 0.7138. The inclusion of sex and CCI score further improved the fit of the model (likelihood ratio 44.41; p < 0.01) and increased the C-index to 0.7187.
conclusionsThe updated Sarculator with HVCs defined as ≥ 13 cases per year was validated using U.S.-only patients. The fit of the model was improved with the addition of sex and CCI score variables, and this should be explored in future studies of the Sarculator model.
Indexed as
Identifiers
41369816What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.